vs
Side-by-side financial comparison of Dime Community Bancshares, Inc. (DCOM) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
Dime Community Bancshares, Inc. is the larger business by last-quarter revenue ($123.8M vs $85.1M, roughly 1.5× 4D Molecular Therapeutics, Inc.). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 3040.1%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 22.9%).
The Dime Community Bank, originally known as the Dime Savings Bank of Williamsburgh, is a local, FDIC-insured bank headquartered in Hauppauge, New York. Founded in 1864, the bank was originally based in the Williamsburg neighborhood of Brooklyn, New York, and continues to operate with a strong market presence in this area. In 2017, Dime moved its headquarters to Brooklyn Heights. On Monday, February 1, 2021, Bridge Bancorp Inc. and Dime Community Bancshares successfully closed on a merger of ...
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
DCOM vs FDMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $85.1M |
| Net Profit | — | $19.4M |
| Gross Margin | — | — |
| Operating Margin | 38.6% | 17.3% |
| Net Margin | — | 22.8% |
| Revenue YoY | 3040.1% | 8508900.0% |
| Net Profit YoY | — | 139.1% |
| EPS (diluted) | $0.68 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $85.1M | ||
| Q3 25 | $115.6M | $90.0K | ||
| Q2 25 | $109.7M | $15.0K | ||
| Q1 25 | $103.8M | $14.0K | ||
| Q4 24 | $3.9M | $1.0K | ||
| Q3 24 | $87.6M | $3.0K | ||
| Q2 24 | $87.3M | $5.0K | ||
| Q1 24 | $82.0M | $28.0K |
| Q4 25 | — | $19.4M | ||
| Q3 25 | $27.7M | $-56.9M | ||
| Q2 25 | $29.7M | $-54.7M | ||
| Q1 25 | $21.5M | $-48.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.3M | $-43.8M | ||
| Q2 24 | $18.5M | $-35.0M | ||
| Q1 24 | $17.7M | $-32.4M |
| Q4 25 | 38.6% | 17.3% | ||
| Q3 25 | 34.7% | -67983.3% | ||
| Q2 25 | 36.6% | -396373.3% | ||
| Q1 25 | 27.6% | -383007.1% | ||
| Q4 24 | -433.6% | — | ||
| Q3 24 | 20.8% | -1704400.0% | ||
| Q2 24 | 29.8% | -849120.0% | ||
| Q1 24 | 29.6% | -136200.0% |
| Q4 25 | — | 22.8% | ||
| Q3 25 | 23.9% | -63195.6% | ||
| Q2 25 | 27.1% | -364386.7% | ||
| Q1 25 | 20.7% | -342657.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | 15.2% | -1461433.3% | ||
| Q2 24 | 21.2% | -699060.0% | ||
| Q1 24 | 21.6% | -115717.9% |
| Q4 25 | $0.68 | $0.43 | ||
| Q3 25 | $0.59 | $-1.01 | ||
| Q2 25 | $0.64 | $-0.98 | ||
| Q1 25 | $0.45 | $-0.86 | ||
| Q4 24 | $-0.58 | — | ||
| Q3 24 | $0.29 | $-0.79 | ||
| Q2 24 | $0.43 | $-0.63 | ||
| Q1 24 | $0.41 | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $505.7M |
| Total Assets | $15.3B | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $402.7M | ||
| Q3 25 | — | $305.1M | ||
| Q2 25 | — | $293.2M | ||
| Q1 25 | — | $321.4M | ||
| Q4 24 | — | $424.9M | ||
| Q3 24 | — | $501.9M | ||
| Q2 24 | — | $541.9M | ||
| Q1 24 | — | $525.9M |
| Q4 25 | $1.5B | $505.7M | ||
| Q3 25 | $1.5B | $369.0M | ||
| Q2 25 | $1.4B | $420.9M | ||
| Q1 25 | $1.4B | $469.7M | ||
| Q4 24 | $1.4B | $510.6M | ||
| Q3 24 | $1.3B | $552.9M | ||
| Q2 24 | $1.3B | $588.3M | ||
| Q1 24 | $1.2B | $600.6M |
| Q4 25 | $15.3B | $566.7M | ||
| Q3 25 | $14.5B | $424.0M | ||
| Q2 25 | $14.2B | $473.6M | ||
| Q1 25 | $14.1B | $515.7M | ||
| Q4 24 | $14.4B | $560.4M | ||
| Q3 24 | $13.7B | $604.0M | ||
| Q2 24 | $13.5B | $620.1M | ||
| Q1 24 | $13.5B | $629.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $186.6M | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $186.6M | $28.6M | ||
| Q3 25 | $52.1M | $-46.5M | ||
| Q2 25 | $23.1M | $-43.4M | ||
| Q1 25 | $65.4M | $-47.8M | ||
| Q4 24 | $99.1M | $-134.6M | ||
| Q3 24 | $-33.3M | $-29.4M | ||
| Q2 24 | $12.6M | $-30.2M | ||
| Q1 24 | $30.7M | $-29.1M |
| Q4 25 | — | $28.5M | ||
| Q3 25 | $51.2M | $-46.6M | ||
| Q2 25 | $20.4M | $-43.4M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | $-138.4M | ||
| Q3 24 | $-34.1M | $-31.2M | ||
| Q2 24 | $9.2M | $-30.6M | ||
| Q1 24 | — | $-29.8M |
| Q4 25 | — | 33.5% | ||
| Q3 25 | 44.3% | -51765.6% | ||
| Q2 25 | 18.6% | -289620.0% | ||
| Q1 25 | — | -345635.7% | ||
| Q4 24 | — | -13837100.0% | ||
| Q3 24 | -38.9% | -1038966.7% | ||
| Q2 24 | 10.5% | -611840.0% | ||
| Q1 24 | — | -106421.4% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.7% | 101.1% | ||
| Q2 25 | 2.4% | 440.0% | ||
| Q1 25 | — | 4507.1% | ||
| Q4 24 | — | 378600.0% | ||
| Q3 24 | 0.9% | 59266.7% | ||
| Q2 24 | 3.9% | 6980.0% | ||
| Q1 24 | — | 2535.7% |
| Q4 25 | — | 1.47× | ||
| Q3 25 | 1.88× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 3.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.50× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 1.74× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
